A multi-site trial of a novel nutritional supplement (taurine, omega-3 fatty acids, zinc, antioxidants, and lutein) and micro-current stimulation in the treatment of atrophic (dry) age-related macular degeneration

ISRCTN ISRCTN57556290
DOI https://doi.org/10.1186/ISRCTN57556290
Secondary identifying numbers AMI-P-307-C-001
Submission date
27/12/2006
Registration date
28/12/2006
Last edited
25/09/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Francis Cangemi
Scientific

119 Prospect Street
Ridgewood, NJ
7450
United States of America

Study information

Study designRandomised prospective investigator, subject and sponsor masked trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymTOZAL
Study objectives1. A novel nutritional supplement containing antioxidants and omega-3 fatty acids improves visual acuity in patients with atrophic (dry) age-related macular degeneration.
2. Micro-current stimulation in combination with a novel nutritional supplement containing antioxidants and omega-3 fatty acids improves visual acuity in patients with atrophic (dry) age-related macular degeneration.
Ethics approval(s)Independent Ethics Committee/Institutional Review Board approvals were received in April 2004 from the University of California Irvine Medical Center and Ohio State University.
Health condition(s) or problem(s) studiedAtrophic (dry) age-related macular degeneration
InterventionNutritional supplement for six months consisting of vitamin A 10,000 IU, beta-carotene 18,640 IU, vitamin E 200 IU, vitamin C 452 IU, zinc 69.6 mg, lutein 8 mg, taurine 400 mg, omega-3 fatty acids 300 mg in combination with a micro-current stimulation device or a sham micro-current stimulation device (randomised).
Intervention typeSupplement
Primary outcome measureMeasure the change in visual acuity from baseline at six months.
Secondary outcome measuresMeasure objective signs of improved macular function.
Overall study start date01/04/2004
Completion date05/04/2005

Eligibility

Participant type(s)Patient
Age groupSenior
SexNot Specified
Target number of participants80
Key inclusion criteria1. Signed written consent
2. Between the ages of 50 and 90, inclusive
3. Any race or gender
4. Diagnosis of nonexudative (dry) Age-related Macular Degeneration (AMD) in at least one eye having more than ten large soft drusen 63 um in diameter, within 3,000 um of the fovea centre, documented on macular exam, retinal angiography and fundus photographs
5. Able to understand and comply with the requirements of the trial
6. Best Corrected Visual Acuity (BCVA) in the trial eye(s) of 20/32 to 20/125 inclusive as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) (logMAR)
7. Subjects must not have conditions that limit the view to the fundus (e.g. vitreous haemorrhage, cataracts, an epiretinal membrane). All subjects with more than or equal to 2+ nuclear opacities and/or significant central opacity (Posterior SubCapsular opacity [PSC] or Anterior SubCapsular opacity [ASC]) more than 1+ will undergo Potential Acuity Meter (PAM) testing. If the vision is more than or equal to two lines improved on PAM over standard acuity measurement then the subject will not be eligible for the trial
8. Subjects must be available for a minimum trial duration of approximately six months
9. Subjects must agree to take only the nutritional supplement that is provided during this study
10. Subjects or eyes must not meet any of the exclusion criteria
Key exclusion criteriaAny of the following excluded a subject from the trial:
1. Currently enrolled in an ophthalmic clinical trial
2. Eyes with concomitant macular or choroidal disorders other than AMD and with indefinite signs of AMD
3. Eyes with a diagnosis of exudative (wet) AMD with active SubRetinal NeoVascularisation (SRNV) or Choroidal NeoVascularisation (CNV) lesions requiring laser photocoagulation in the study eye
4. Subjects with significant ocular lens opacities causing vision decrease
5. Subjects with amblyopia
6. Subjects with optic nerve disease (neuropathy, atrophy, papilledema), unstable glaucoma as defined by intraocular pressures greater than 25 mmHg, three or more glaucoma medications, C/D of 0.8 or greater and visual fields consistent with glaucoma; history of retina-vitreous surgery, degenerative myopia, active posterior intraocular inflammatory disease, chronic use of topical ocular steroid medications, vasoproliferative retinopathies (other than AMD), rhegmatogenous retinal detachment, and inherited macular dystrophies
7. Subjects with demand type pacemakers or epilepsy
8. Subjects with uncontrolled hypertension (defined as diastolic of 90 or greater and systolic of 150 or greater)
9. Subjects with recent history (within the previous year) of cerebral vascular disease manifested with Transient Ischaemic Attacks (TIA’s) or cerebral vascular accidents (CVA’s)
10. Subjects with a history of Acquired Immune Deficiency Syndrome (AIDS)
11. Subjects who have received any previous experimental procedure in either eye or the use of any investigational drug or treatment within 30 days prior to enrolling in the trial
12. Subjects who have had intraocular surgery in trial eye within three months prior to enrolling in the trial
13. Smokers or any tobacco use
Date of first enrolment01/04/2004
Date of final enrolment05/04/2005

Locations

Countries of recruitment

  • United States of America

Study participating centre

119 Prospect Street
Ridgewood, NJ
7450
United States of America

Sponsor information

Atlantic Medical, Inc. (USA)
Industry

1213 Culbreth Drive
Wilmington, NC
28405
United States of America

Funders

Funder type

Industry

Atlantic Medical, Inc. (USA)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 26/02/2007 Yes No